Why depot antipsychotic drug use in the treatment of psychotic disorders is still important?
An investigation regarding clinical outcome Objective: Clinical outcomes of depot antipsychotic drug (DAPD1 use for noncompliant patients with schizophrenia and delusional disorder were evaluated in this study. Method: Between August 1st 2003 and August 1st 2004, 21 treatment noncompliant patients with schizophrenia and delusional disorder, diagnosed according to DSM-IV at the University of Kocaeli, School of Medicine, Psychotic Disorders Outpatient Clinic, were enrolled into this study of depot antipsychotic drug (fluphenazine decanoate] treatment (DAPD1. Chlorpromazine equivalent antipsychotic drug doses assumed to be used by the patients and the Positive and Negative Syndrome Scale (PANSS] scores, Global Assessment of Functioning (GAR scores, and Clinical Global Impressions severity scale (CGIssl scores were recorded. Fluphenazine decanoate 25 mg was injected to all patients intramuscularly every week in the first month, every two weeks in the second month, and every three weeks in
